Enzon Pharmaceuticals (Enzon Pharmaceuticals) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Enzon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Enzon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Enzon Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Enzon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Enzon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

Enzon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Enzon Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Enzon Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

EZ1:Germany

Address

20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016

Website

http://www.enzon.com

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Executives

Randolph C Read	director	C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone	director	C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick	director	C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper	other: See explanation of responses	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc	other: See explanation of responses	2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper	other: See explanation of responses	6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc.	other: See Footnote 1	600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp.	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman	10 percent owner, other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn	10 percent owner	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein	officer: VP-Finance and PFO
Jonathan Christodoro	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121